Drug seminar focuses on economies of biosimilars

The economics of biologics will grow more challenging, especially as demand increases as the financial model of the industry has been built on aggressive pricing of drugs intended for use in a limited number of patients, according a local consultant.

In a pharmaceutical seminar on November 18, SDS chief consultant said that biosimilars are poised to exploit the opportunity arising from expir...